XBIO Xenetic Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534525 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.5%
TTM net income YoY-16.0%
TTM EPS YoY24.0%
Revenue 3-yr CAGR7.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-129.6%
Net margin-123.7%
FCF margin—
EBITDA margin—
Returns
ROE-87.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.52x
Leverage & solvency
Liabilities / assets30.1%
Debt / equity0.00x
Current ratio3.15x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.98M | $2.50M | $2.54M | $1.71M | $1.16M |
| R&D expense | $3.07M | $3.29M | $3.49M | $4.77M | $3.16M |
| SG&A expense | $2.75M | $3.42M | $3.56M | $3.65M | $3.74M |
| Operating income | -$2.83M | -$4.20M | -$4.52M | -$6.72M | -$5.75M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.68M | -$3.96M | -$4.13M | -$6.55M | -$5.65M |
| EBITDA | — | — | — | -$6.72M | -$5.75M |
| EPS (basic) | -1.58 | -2.57 | -2.71 | -4.61 | -0.55 |
| EPS (diluted) | -1.58 | -2.57 | -2.71 | -4.61 | -0.55 |
| Weighted avg. shares (diluted) | 1.70M | 1.54M | 1.53M | 1.42M | 10.28M |
| Banking | |||||
| Net interest income | $147,997 | $249,861 | $355,757 | $167,152 | $100,467 |
| Balance sheet | |||||
| Cash & equivalents | $7.88M | $6.17M | $8.98M | $13.10M | $18.24M |
| Current assets | $8.05M | $6.59M | $9.59M | $13.65M | $18.72M |
| PP&E, net | — | — | — | $0 | $0 |
| Total assets | $8.36M | $6.90M | $10.61M | $14.72M | $19.82M |
| Current liabilities | $968,025 | $894,263 | $809,585 | $1.07M | $1.42M |
| Total liabilities | $968,025 | $894,263 | $809,585 | $1.07M | $1.42M |
| Shareholders' equity | $7.40M | $6.01M | $9.80M | $13.65M | $18.39M |
| Shares outstanding | 2.29M | 1.54M | 1.54M | 1.52M | 13.44M |
| Cash flow statement | |||||
| Operating cash flow | -$2.29M | -$2.82M | -$4.11M | -$4.65M | -$4.74M |
| Investing cash flow | — | — | $0 | -$500,000 | $0 |
| Financing cash flow | $4.00M | $0 | — | $0 | $11.45M |
| Depreciation & amortization | — | — | — | $0 | $0 |
| Stock-based compensation | $64,787 | $171,814 | $283,085 | $511,480 | $410,437 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.